Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Westlake Closes $16 Million A Round for Stem Cell Cellular Therapies

publication date: Jan 26, 2021

Westlake Therapeutics of Hangzhou closed a $16 million Series A funding to develop red blood cell-based cellular medicines. The company develops its candidates by extracting hematopoietic stem cells, transforming them into medicine-carriers, and then transfusing them back into human bodies. The A round was led by CD Capital and included Sequoia Capital China. One year ago, Westlake raised $16 million in a Pre-A round from the Westlake Fund and Tasly Pharma, which remains a key investor. More details....

Stock Symbol: (SHA: 600535)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital